Proposing new approaches for dating young volcanic eruptions by luminescence methods

The application of luminescence dating to young volcanic sediments has been first investigated over three decades ago, but it was only with the technical innovations of the last decade that such analyses became viable. While current analytical procedures show promise for dating late Quaternary volcanic events, most efforts have been aimed at unconsolidated volcanic tephra. Investigations into direct dating of lava flows or of non-heated volcanoclastics like phreatic explosion layers, however, remain scarce. These volcanic deposits are of common occurrence and represent important chrono- and volcanostratigraphic markers. Their age determination is therefore of great importance in volcanologic, tectonic, geomorphological and climate studies. In this article, we propose the use of phreatic explosion deposits and xenolithic inclusions in lava flows as target materials for luminescence dating applications. The main focus is on the crucial criterion whether it is probable that such materials experience complete luminescence signal resetting during the volcanic event to be dated. This is argued based on the findings from existing literature, model calculations and laboratory tests.

Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report

Hypereosinophilic syndromes are a heterogeneous group of uncommon disorders characterized by the presence of marked peripheral blood eosinophilia, tissue eosinophilia, or both, resulting in a wide variety of clinical manifestations. Although corticosteroids are the first-line therapy for many of these disorders, approaches to the treatment of patients who do not tolerate or are unresponsive to corticosteroids are poorly standardized. A multidisciplinary group of 37 clinicians and scientists participated in a workshop held in May 2005 in Bern, Switzerland to discuss current and future approaches to therapy for 3 eosinophil-mediated disorders: hypereosinophilic syndrome, Churg-Strauss syndrome, and eosinophil-associated gastrointestinal disease. The goal of the workshop was to summarize available data regarding treatment of these disorders to identify the most promising therapies and approaches for further study. There was consensus among all of the participants that the identification of markers of disease progression to assess treatment responses is a research priority for all 3 disorders. Furthermore, the need for newer therapeutic strategies and novel drugs, as well as multicenter trials to assess all treatment modalities, was emphasized.